Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 5 of 14

10. Absci Corp (NASDAQ:ABSI)

Number of Hedge Fund Holders In Q4 2024: 18

Absci Corp (NASDAQ:ABSI) sells itself as an AI-integrated drug company.

The stock is up significantly so far in 2025 as it announced a collaboration with AMD. This included a $20 million strategic investment from AMD through private investment in public equity (PIPE) and will involve deploying AMD Instinct™ accelerators and ROCm™ software to power Absci’s AI drug discovery workloads.

It also partnered up with Invetx in January and advanced its ABS-101 drug and has plans to submit an Investigational New Drug application in Q1 2025.

The consensus price target of $8.57 implies 112.16% upside.

ABSI is up 54.58% year-to-date.

Page 5 of 14